Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2019-11-04 Regulatory Filings
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 99% confidence The document text is extremely short (401 characters) and explicitly states, "Please read the full announcement in the attached PDF" and provides a link to a document titled "2019_48_Stock_Buybackprogram_EN". This structure indicates an announcement about a transaction rather than the detailed report itself. The content specifically concerns a 'stock buyback program,' which falls under the category of the company transacting in its own shares. Therefore, the most appropriate classification is Transaction in Own Shares (POS). Given the brevity and the instruction to read an attachment, it could also be considered a Report Publication Announcement (RPA), but POS is more specific to the subject matter (buyback). Since the subject is clearly defined as a buyback, POS is preferred over the general RPA/RNS fallback.
2019-11-04 English
Transaction in Own Shares 2019
Transaction in Own Shares Classification · 100% confidence The document text is very short (427 characters) and is titled 'Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram' (Transactions related to Novozymes' share buyback program). It explicitly instructs the reader to 'Læs venligst hele meddelelsen i vedhæftede fil' (Please read the entire announcement in the attached file) and provides a link to a document. This structure strongly indicates an announcement about a transaction rather than the detailed report itself. Since the content specifically concerns the company buying back its own shares, the most appropriate classification is 'Transaction in Own Shares' (POS). Although it could potentially be an RPA if it were just announcing the release of a report, the specific subject matter (share repurchase) points directly to POS, and the announcement itself is the primary content provided here.
2019-11-04 English
Transactions under Novozymes’ stock buyback program
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement of transactions related to Novozymes' share buyback program, including the number of shares bought, prices, transaction values, and dates. It references compliance with market abuse regulations and provides detailed trading data. There is no indication of financial statements, earnings data, or management discussion. The content focuses exclusively on the company's repurchase of its own shares. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on share repurchase activities. The document length and detail confirm it is the report itself, not just an announcement of a report publication.
2019-11-04 English
Transactions under Novozymes’ stock buyback program
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement of transactions under Novozymes' stock buyback program, including number of shares purchased, transaction values, and dates. It references compliance with Market Abuse Regulation and provides detailed trading data. There is no indication of financial statements, earnings, management discussion, or other report types. The content is focused on the company's repurchase of its own shares, which fits the definition of a Transaction in Own Shares (POS) filing. The document length is substantial and contains detailed transaction data, confirming it is not a mere announcement of a report but the actual transaction disclosure.
2019-11-04 English
Ester Baiget appointed new CEO of Novozymes
Board/Management Information Classification · 100% confidence The document is a corporate announcement regarding the appointment of a new CEO (Ester Baiget) for Novozymes. It details her background, the transition from the previous CEO, and includes contact information for Investor Relations. This falls squarely under the category of management changes.
2019-10-30 Danish
Ester Baiget appointed new CEO of Novozymes
Board/Management Information Classification · 100% confidence The document is a formal company announcement regarding the appointment of a new CEO (Ester Baiget) at Novozymes. This falls directly under the category of changes in senior management.
2019-10-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.